# Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

> **NCT00484341** · PHASE2 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 69 (actual)

## Conditions studied

- Metastatic Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** low-dose NGR-hTNF
- **DRUG:** high-dose NGR-hTNF
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00484341
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484341, "Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00484341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*